These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27557819)

  • 1. A Review on Plasmodium falciparum-Protein Farnesyltransferase Inhibitors as Antimalarial Drug Targets.
    Sharma K
    Curr Drug Targets; 2017; 18(14):1676-1686. PubMed ID: 27557819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
    Nallan L; Bauer KD; Bendale P; Rivas K; Yokoyama K; Hornéy CP; Pendyala PR; Floyd D; Lombardo LJ; Williams DK; Hamilton A; Sebti S; Windsor WT; Weber PC; Buckner FS; Chakrabarti D; Gelb MH; Van Voorhis WC
    J Med Chem; 2005 Jun; 48(11):3704-13. PubMed ID: 15916422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity.
    Ohkanda J; Lockman JW; Yokoyama K; Gelb MH; Croft SL; Kendrick H; Harrell MI; Feagin JE; Blaskovich MA; Sebti SM; Hamilton AD
    Bioorg Med Chem Lett; 2001 Mar; 11(6):761-4. PubMed ID: 11277514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials.
    Olepu S; Suryadevara PK; Rivas K; Yokoyama K; Verlinde CL; Chakrabarti D; Van Voorhis WC; Gelb MH
    Bioorg Med Chem Lett; 2008 Jan; 18(2):494-7. PubMed ID: 18077162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel N-(4-Piperidinyl)benzamide antimalarials with mammalian protein farnesyltransferase inhibitory activity.
    Ryckebusch A; Gilleron P; Millet R; Houssin R; Lemoine A; Pommery N; Grellier P; Sergheraert C; Hénichart JP
    Chem Pharm Bull (Tokyo); 2005 Oct; 53(10):1324-6. PubMed ID: 16204993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria.
    Kandepedu N; Gonzàlez Cabrera D; Eedubilli S; Taylor D; Brunschwig C; Gibhard L; Njoroge M; Lawrence N; Paquet T; Eyermann CJ; Spangenberg T; Basarab GS; Street LJ; Chibale K
    J Med Chem; 2018 Jul; 61(13):5692-5703. PubMed ID: 29889526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmodium kinases as targets for new-generation antimalarials.
    Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
    Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability.
    Carrico D; Ohkanda J; Kendrick H; Yokoyama K; Blaskovich MA; Bucher CJ; Buckner FS; Van Voorhis WC; Chakrabarti D; Croft SL; Gelb MH; Sebti SM; Hamilton AD
    Bioorg Med Chem; 2004 Dec; 12(24):6517-26. PubMed ID: 15556768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicases - feasible antimalarial drug target for Plasmodium falciparum.
    Tuteja R
    FEBS J; 2007 Sep; 274(18):4699-704. PubMed ID: 17824956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel lead structures for antimalarial farnesyltransferase inhibitors.
    Kettler K; Sakowski J; Wiesner J; Ortmann R; Jomaa H; Schlitzer M
    Pharmazie; 2005 May; 60(5):323-7. PubMed ID: 15918578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability.
    Bulbule VJ; Rivas K; Verlinde CL; Van Voorhis WC; Gelb MH
    J Med Chem; 2008 Feb; 51(3):384-7. PubMed ID: 18198825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box.
    Tiwari NK; Reynolds PJ; Calderón AI
    Molecules; 2016 Mar; 21(4):424. PubMed ID: 27043496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.
    Wadood A; Ghufran M; Hassan SF; Khan H; Azam SS; Rashid U
    Pharm Biol; 2017 Dec; 55(1):19-32. PubMed ID: 27650666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials.
    Bendale P; Olepu S; Suryadevara PK; Bulbule V; Rivas K; Nallan L; Smart B; Yokoyama K; Ankala S; Pendyala PR; Floyd D; Lombardo LJ; Williams DK; Buckner FS; Chakrabarti D; Verlinde CL; Van Voorhis WC; Gelb MH
    J Med Chem; 2007 Sep; 50(19):4585-605. PubMed ID: 17722901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
    Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials.
    Kohring K; Wiesner J; Altenkämper M; Sakowski J; Silber K; Hillebrecht A; Haebel P; Dahse HM; Ortmann R; Jomaa H; Klebe G; Schlitzer M
    ChemMedChem; 2008 Aug; 3(8):1217-31. PubMed ID: 18470859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives.
    Korotchenko V; Sathunuru R; Gerena L; Caridha D; Li Q; Kreishman-Deitrick M; Smith PL; Lin AJ
    J Med Chem; 2015 Apr; 58(8):3411-31. PubMed ID: 25654185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmodium falciparum Thioredoxin Reductase (PfTrxR) and Its Role as a Target for New Antimalarial Discovery.
    McCarty SE; Schellenberger A; Goodwin DC; Fuanta NR; Tekwani BL; Calderón AI
    Molecules; 2015 Jun; 20(6):11459-73. PubMed ID: 26111176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase.
    Eastman RT; White J; Hucke O; Yokoyama K; Verlinde CL; Hast MA; Beese LS; Gelb MH; Rathod PK; Van Voorhis WC
    Mol Biochem Parasitol; 2007 Mar; 152(1):66-71. PubMed ID: 17208314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new antimalarial drug combination].
    Nau JY
    Rev Med Suisse; 2010 May; 6(247):942-3. PubMed ID: 20499586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.